196706-13-5

Upstream product

• 196706-15-7 (E)-(S)-2-Benzyl-7-methyl-oct-4-enoic acid ((1S,2S)-2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide 
• 196706-11-3 (E)-(S)-2-Benzyl-7-methyl-oct-4-enoic acid ((1R,2R)-2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide 
• 196706-10-2 (E)-7-Methyl-oct-4-enoic acid ((1R,2R)-2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide 
• 590-86-3 isovaleraldehyde 
• 645-45-4 hydrocinnamic acid chloride 
• 14980-86-0 N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methyl-3-phenylpropanamide 
• 179617-62-0 7-methyl-oct-4-enoic acid 
• 103335-72-4 trans-1-Bromo-5-methylhex-2-ene 
• 4798-46-3 5-methylhex-1-en-3-ol 
• 196706-12-4 (1'R,3R,5S)-3-benzyl-5-(1'-bromo-3'-methylbutyl)dihydrofuran-2-one 

Downstream Products

• 196706-14-6 (1S,2'S,4'R)-5-[1-(4'-benzyl-5'-oxo-tetrahydrofuran-2'-yl)-3-methylbutyl]carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics

The structure-based design, chemical synthesis, and biological evaluation of various ketomethylene-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of a peptidomimetic binding determinant and an e